国内外制药企业质量管理成熟度现状及对我国药品生产监管的启示

摘要/Abstract

摘要： 随着我国药品监管机制的日益成熟，国内制药企业的质量体系建设日趋健全，但质量管理成熟度与头部跨国制药企业相比仍有差距。本研究通过梳理美国食品药品管理局(FDA）质量量度项目、质量管理成熟度项目的实施内容，调研跨国制药企业质量管理成熟度现状，比照剖析了我国制药企业在质量管理过程中药品质量管理成熟度的现状，总结了质量绩效指标策略、质量体系运行有效性、持续改进质量文化建设等三个方面存在的问题，并提出了通过转变药品生产监管理念、加强质量管理成熟度研究、借助数字化手段赋能我国制药企业质量管理成熟度提升的建议。

关键词: font-size:medium, ">制药企业；质量管理成熟度；质量体系；药品监管；智慧监管

Abstract: With the increasing maturity of domestic drug supervision mechanism， the quality management system of domestic drug manufacturers is also becoming more well-established， but there is still a gap between domestic and top multinational drug manufacturers on quality management maturity. Through the review of the FDA quality metrics&quality management maturity program and the status survey of the quality management maturity of multinational drug manufacturers， this paper comparatively analyzed the situation of quality management maturity of domestic drug manufactures, and summarize the problem existing in the quality management of domestic enterprises from the aspects of quality performance indicator strategy，effectiveness of quality system operation， and continuous improvement quality culture， and it is proposed that by transforming the mindset of drug production supervision， strengthening the research on quality management maturity， and using digital means to empower the improvement of quality management maturity of domestic drug manufacturers.

Key words: font-size:medium, ">Drug manufacturers； Quality management maturity； Quality system； Drug supervision； Intelligent supervision

中图分类号:

胡位歆, 和金周. 国内外制药企业质量管理成熟度现状及对我国药品生产监管的启示[J]. 中国医药导刊, 2022, 24(8): 740-745.

HU Weixin, HE Jinzhou. Current Situation of Quality Management Maturity of Domestic and International Drug Manufacturers and Its Implications for Drug Production Supervision[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2022, 24(8): 740-745.

参考文献

[1]International Conference on Harmonisation. Guidance on Q10 Pharmaceutical Quality System [EB/OL].(2009-04-08）[2022-8-17].https://https://www.federalregister.gov/documents/2009/04/08/E9-7875/international-conference-on-harmonisation-guidance-on-q10-pharmaceutical-quality-system-availability.
     [2]FDA.Quality Metrics for Drug Manufacturing[EB/OL].（2022-03-09）[2022-08-17].https://www.fda.gov/drugs/pharmaceutical-quality-resources/quality-metrics-drug-manufacturing.
     [3]ISPE.Quality metrics initiative: A report from the pilot project-wave1 [EB/OL].（2015-06-01）[2022-08-17]. https://ispe.org/products/ispe-quality-metrics-initiative-wave-1-report.
     [4]ISPE.Quality metrics initiative: Quality metrics pilot program wave 2 [EB/OL].（2016-06-01）[2022-08-17]. https://ispe.org/products/ispe-quality-metrics-initiative-wave-2-report.
     [5]ISPE.Quality Management Maturity Program: Advancing Pharmaceutical Quality[EB/OL].（2020-10-08）[2022-08-17]. https://ispe.org/pharmaceutical-engineering/ispeak/ispe-quality-management-maturity-program-advancing-pharmaceutical.
     [6]FDA.CDER Quality Management Maturity[EB/OL].（2022-05-04）[2022-08-17]. https://www.fda.gov/drugs/pharmaceutical-quality-resources/cder-quality-management-maturity.
     [7]ISPE – PDA Guide to Improving Quality Culture in Pharmaceutical Manufacturing Facilities[EB/OL].（2019-10-07)[2022-08-17]. https://ispe.org/news/ispe-pda-create-guide-improving-quality-culture-pharmaceutical-industry.
     [8]国家药品监督管理局.国务院办公厅印发《关于建立职业化专业化药品检查员队伍的意见》[EB/OL] .（2019-07-18)[2022-08-17]. https://www.nmpa.gov.cn/yaopin/ypjgdt/20190718174601792.html.
     [9]国家药品监督管理局.国务院办公厅印发《关于全面加强药品监管能力建设的实施意见》[EB/OL] .（2021-05-10)[2022-08-17].https://www.nmpa.gov.cn/zhuanti/ypjgssyj/ypjgssyjjj/20210510191205129.html.
     [10]国家药品监督管理局.国家药品监督管理局启动药品检查合作计划（PIC/S）预加入申请工作[EB/OL] .（2021-09-29)[2022-08-17].https://www.nmpa.gov.cn/yaopin/ypjgdt/20210929162552105.html.
     [11]Steven Lynn， Susan Schniepp， Justin Anahory.Getting drug quality right the first time [EB/OL].(2022-04-20)[2022-08-17]. https://www.pharmamanufacturing.com/articles/2022/getting-drug-quality-right-the-first-time/.
     [12]王霞，陈恒青，朱建伟.质量管理体系中实施质量量度对制药工业的意义[J].中国医药工业杂志，2020， 51(4): 545-550.
     [13]包敏芝，胡延熹.质量量度在国内药品生产企业中的应用[J].上海医药，2016，37(23): 69-72.
     [14]国家药品监督管理局.中华人民共和国药品管理法 [EB/OL].(2019-08-27）[2022-08-17]. https://www.nmpa.gov.cn/xxgk/fgwj/flxzhfg/20190827083801685.html.
     [15]张景辰.加强事中监管，促进药品产业的供给侧改善—FDA质量量度计划的启示[J].中国食品药品监管，2016，（4）：56-58.
     [16]杨依晗，赵燕君，高惠君.美国食品和药物管理局质量量度管理的简介及启示[J].中国新药与临床杂志，2016，35(4):260-263.
     [17]孙敏，谭德讲.用合理的质量量度指标助力药品质量的科学监管[J]. 中国食品药品监管，2021，(2):37-43.

快速检索引用检索图表检索高级检索